Vista Capital has wholly purchased pharmaceutical business Laboratorios Indas from the Arochena family for around EUR 360m. It is understood that the private equity firm has faced competition from its peers Mercapital, Nmás1 and Ibersuizas, before signing an exclusivity agreement with the company’s owners in early February.
Also backing the biotech startup were the Zürcher Kantonalbank and Greencross Medical Science Corp
Company plans to use the fresh capital to further expand, develop new features and scale up its team
EVentures, 468 Capital and HV Holtzbrinck back the round for the climate change mitigation app
Clessidra has been in negotiations for the acquisition of the Italian wine producer since February 2020